Low normal cerebrospinal fluid Aß42 levels predict clinical progression in nondemented subjects.
Ann Neurol
; 81(5): 749-753, 2017 May.
Article
em En
| MEDLINE
| ID: mdl-28318059
ABSTRACT
We studied whether continuous lower normal cerebrospinal fluid (CSF) amyloid ß1-42 (≥640pg/ml) levels were related with rate of clinical progression in a sample of 393 nondemented memory clinic patients. Lower normal levels were associated with faster clinical progression, and this depended on baseline cognitive status (subjective cognitive decline hazard ratio [HR] = 0.57, p < 0.05; mild cognitive impairment HR = 0.19, p < .01), indicating that normal CSF amyloid levels do not exclude incident Alzheimer disease. These findings suggest that research on preclinical markers for Alzheimer disease should take the continuum of CSF amyloid ß1-42 levels within the normal range into account. Ann Neurol 2017;81749-753.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fragmentos de Peptídeos
/
Peptídeos beta-Amiloides
/
Progressão da Doença
/
Doença de Alzheimer
/
Disfunção Cognitiva
/
Transtornos da Memória
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article